Pluristem Therapeutics Inc. (PSTI) - 10-Q Summary
Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (formerly A.I. Software Inc.)
Reporting Period: Six months ended December 31, 2008 (Unaudited)
Business Stage: Development Stage Company. The company is focused on the research and development of adherent stromal cells production technology and cell therapy products. It has not generated any revenues or product sales since inception.
Key Financial Metrics
| Metric (in thousands USD) | Six Months Ended Dec 31, 2008 | Six Months Ended Dec 31, 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,075) | $(4,810) |
| Loss Per Share (Basic & Diluted) | $(0.35) | $(0.79) |
| Cash and Cash Equivalents (Ending) | $2,193 | $462 |
| Net Cash Used in Operating Activities | $(2,085) | $(2,180) |
| Net Cash Provided by Financing Activities | $3,020 | $1,463 |
| Total Assets | $4,381 | $3,584 (June 30, 2008) |
| Accumulated Deficit | $(29,091) | $(26,016) (June 30, 2008) |
| Working Capital | $2,043 | N/A |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 36% to $3.075 million from $4.810 million in the prior year period. This improvement was driven by a significant reduction in stock-based compensation expenses due to a decline in stock price and increased grant participation from the Israeli Office of the Chief Scientist.
- Expense Reduction:
- R&D Expenses (Net): Decreased 30% to $1.302 million (from $1.871 million). For the three months ended Dec 31, 2008, net R&D expenses dropped 96% to $39,000.
- G&A Expenses: Decreased 45% to $1.707 million (from $3.085 million), primarily due to reduced stock-based compensation and cuts in investor relations and public relations costs.
- Liquidity Improvement: Cash and cash equivalents increased by $1.87 million to $2.193 million. This was achieved through the sale of marketable securities ($1.113 million proceeds) and significant equity financing ($3.02 million net cash from financing activities).
- Debt: Long-term obligations remain minimal ($28 thousand). The company has no significant interest-bearing debt outstanding as of the reporting date.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the company's financial condition raises substantial doubt about its ability to continue as a going concern. The company has an accumulated deficit of $29.1 million and expects to incur losses in the foreseeable future.
- Capital Requirements: Management estimates operating cash expenses for the next twelve months to be approximately $6.0 million. The company plans to finance operations through equity placements and R&D grants. There is no assurance that acceptable financing can be obtained.
- Revenue Outlook: No product sales are expected in the next 12 months. Products are not expected to be ready for sale for at least three years. Potential revenue sources include licensing technology.
- Key Milestones:
- Scaling up 3-D PluriX Bioreactor operations to commercial capabilities.
- Initiating Phase I clinical trials in the USA (pending FDA IND approval) and Europe.
- Obtaining pre-clinical data for additional indications.
- Recent Financing: The company raised approximately $3.3 million in gross proceeds during the six months ended Dec 31, 2008, through multiple private placements of common stock and warrants. Subsequent events (Jan 2009) indicate additional fundraising of approximately $1.2 million.
- Risks: Risks include failure to secure additional funding, inability to achieve regulatory approvals, and the inherent uncertainties of clinical trials. The company also noted a potential dispute regarding a price floor provision in a May 2007 agreement, though management believes it is unenforceable.
Investor Verification Checklist
- Cash Runway: Verify if the current cash balance ($2.193 million) is sufficient to cover the estimated $6.0 million annual burn rate without immediate additional financing.
- Dilution Impact: Review the terms of recent and subsequent equity issuances (Aug, Sep, Nov/Dec 2008, and Jan 2009) to assess the dilution effect on existing shareholders.
- Grant Reliance: Confirm the status of the grant application to the Office of the Chief Scientist (OCS) and the European Union Seventh Framework Programme, as these are critical non-dilutive funding sources.
- Clinical Trial Timeline: Monitor the status of the FDA Investigational New Drug (IND) application and European regulatory approvals required to begin Phase I trials.
- Legal Disputes: Investigate the potential legal implications of the May 2007 agreement price floor provision and the company's strategy to resolve it via investor releases.